Arrowstreet Capital Limited Partnership Has $38.34 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Arrowstreet Capital Limited Partnership lifted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 2,103.7% in the second quarter, Holdings Channel.com reports. The institutional investor owned 4,278,555 shares of the biotechnology company’s stock after purchasing an additional 4,084,403 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in BioCryst Pharmaceuticals were worth $38,336,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of BCRX. Assenagon Asset Management S.A. lifted its position in BioCryst Pharmaceuticals by 25,631.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company’s stock worth $32,441,000 after acquiring an additional 3,606,566 shares during the last quarter. Doliver Advisors LP grew its position in shares of BioCryst Pharmaceuticals by 269.1% in the second quarter. Doliver Advisors LP now owns 274,328 shares of the biotechnology company’s stock valued at $2,458,000 after purchasing an additional 200,000 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 244.1% in the first quarter. Acadian Asset Management LLC now owns 670,361 shares of the biotechnology company’s stock worth $5,023,000 after purchasing an additional 475,564 shares during the period. Millennium Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 382.6% in the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock worth $28,597,000 after purchasing an additional 3,022,769 shares during the period. Finally, Strs Ohio acquired a new position in shares of BioCryst Pharmaceuticals during the 1st quarter worth about $284,000. 85.88% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BCRX. Needham & Company LLC lowered their target price on BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Evercore ISI reiterated an “in-line” rating and set a $8.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Citizens Jmp lowered their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a research note on Wednesday, November 5th. Zacks Research lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Finally, TD Cowen assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 15th. They set a “buy” rating and a $30.00 target price for the company. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Insider Activity

In other news, insider Alane P. Barnes sold 91,004 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $7.10, for a total transaction of $646,128.40. Following the completion of the transaction, the insider directly owned 416,152 shares of the company’s stock, valued at approximately $2,954,679.20. This trade represents a 17.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 161,680 shares of company stock valued at $1,164,401. Corporate insiders own 5.10% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 3.1%

BCRX opened at $7.59 on Friday. The stock has a market cap of $1.60 billion, a PE ratio of -151.80 and a beta of 0.91. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.31. The stock’s 50 day simple moving average is $7.12 and its 200-day simple moving average is $8.35.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The firm had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. During the same period last year, the business earned ($0.07) earnings per share. The firm’s revenue for the quarter was up 36.1% compared to the same quarter last year. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.